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A Yellow Fever Epidemic
ANewGlobal Health Emergency?
Theworstyellowfeverepidemic inAngola since 1986
is rapidly spreading, including the capital, Luanda. In
Angola, the epidemic began in December 2015 and the
laboratory-confirmed outbreak was reported to
the World Health Organization (WHO) on January 21,
2016.1 Angola has had 2023 suspected cases and 258
deaths as of April 26, 2016.1 China, the Democratic
Republic of Congo, andKenya also have reported cases
arising frominfectedtravelers fromAngola.Namibiaand
Zambia also share a long border with Angola, with con-
siderable population movement between the coun-
tries. Similar toother recentepidemics, quick andeffec-
tive action to stop the spread of yellow fever is the
responsibility of the world’s health community.
More than 7 million Angolans have been vacci-
nated, but supply shortages could potentially lead to a
health security crisis if yellow fever spreads within
Africa, Asia (which has never experienced a yellow
fever epidemic), or the Americas (where Aedes mos-
quito vectors transmit yellow fever as well as Zika,
dengue, and chikungunya). The Pan American Health
Organization declared an epidemiological alert on April
22, 2016, for yellow fever in Latin America.2 The WHO
should urgently convene an emergency committee to
mobilize funds, coordinate an international response,
and spearhead a surge in vaccine production. Prior
delays by the WHO in convening emergency commit-
tees for the Ebola virus, and possibly the ongoing Zika
epidemic, cost lives and should not be repeated.3 Act-
ing proactively to address the evolving yellow fever epi-
demic is imperative.
Epidemiology and Diagnosis of Yellow Fever
The yellow fever virus is an arbovirus that belongs to
the flavivirus genus (like Zika, dengue, and West Nile).
(Yellow refers to jaundice caused by liver involvement.)
The virus is transmitted between humans and from
monkeys to humans by mosquitoes, primarily by Aedes
(aegypti) and Hemogogus, in 1 of 3 cycles: (1) urban
yellow fever, (2) jungle (sylvatic) yellow fever, and
(3) intermediate yellow fever. More than 500 million
individuals are at risk in Africa, as are approximately
400 million individuals in Latin America.4 Historically,
well-described outbreaks occurred in the United States
(eg, in 1793 in Philadelphia, Pennsylvania; in 1878 in
Memphis, Tennessee; and in 1905 in New Orleans,
Louisiana) and in Europe in 1730 and 1821.
After an incubation period of 3 to 6 days, an acute
febrile phaseoccurswithmyalgia, headache, backpain,
anorexia, nausea, and sometimes vomiting; symptoms
typically resolve within 1 week. In approximately 1 in 7
individuals, a secondphasequickly followswithhigh fe-
ver, jaundice, bleeding, and kidneydamage,with death
occurring in50%ofpatients;mostof the remaininghalf
fully recover.4 Each year, yellow fever causes an esti-
mated 30000 deaths, mostly in Africa.4
Even with knowledge of the typical clinical mani-
festations and outbreak epidemiology, clinical diagno-
sis can be difficult because yellow fever canmimicmul-
tiple febrile illnesses, including those causing jaundice
andbleeding (suchasacuteviral hepatitis andviral hem-
orrhagic fevers). Laboratory diagnostic tests can de-
tect the virus and specific antibodies in the blood. No
specific antiviral drug or immune therapy exists for yel-
low fever disease.
The Yellow Fever Vaccine
Alicensed, liveattenuated,yellowfevervaccinehasbeen
available for decades, conferring lifelong protection
within 10days inmore than90%of individualswho re-
ceived the vaccine.4 National border rules currently
requireayellowfevercardshowingproof
of vaccinationwithin 10 years for epide-
miologically at-risk travelers. Although
the yellow fever vaccine is well toler-
ated, it is not recommended in nonepi-
demic settings for individuals with se-
vere immunodeficiency, pregnant
women, infants, or individuals with se-
vereeggallergies. Individuals older than60years are at
higher risk for a rare, but serious complication, vaccine-
associated viscerotropic disease. The WHO recom-
mends routine vaccination for children living in at-risk
countries for yellow fever, with community immunity
conferred by vaccination rates of 60% to 80%.4
Mass vaccination campaigns in conjunction with
mosquito control, surveillance, and coordinated re-
sponses are urgently needed in the event of an out-
break. TheWHO serves as the Secretariat for the Inter-
national Coordinating Group for yellow fever vaccine
provision,withpartners suchas theUnitedNations (UN)
Children’s Fund, the International Federation of Red
Cross andRedCrescent Societies, andDoctorsWithout
Borders (Médecins Sans Frontières).4 The Interna-
tional Coordinating Group maintains a vaccine stock-
pile for rapid response;however, a seriousvaccineshort-
age is anticipated if yellow fever spreads to other
countries or regions. Surge capacity is currently limited
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because specific pathogen-free chicken eggs are needed to pro-
duce the vaccine.
On May 2, 2016, the Democratic Republic of Congo an-
nounced plans to vaccinate nearly 2million individuals in Kinshasa
and Kongo Central, suspecting local transmission.5 This campaign,
alongwithAngola, couldbea tippingpoint in exhaustingglobal vac-
cine supplies.
TheWHO’sEmergencyUseAssessmentandListing (EUAL)pro-
cedures, first introduced for the Ebola virus,6 could be adapted to
safeguardtheyellowfevervaccinesupply. Internationalexpertshave
urged using one-fifth of the normal vaccine dose in Angola to avert
acute shortages if the virus spreads.7 If this suggested practice is
carried out, regulatory hurdles would likely be encountered, and
there would also be uncertainty regarding the extent and duration
of immunity, especially in children. Monath et al7 recently recom-
mended “invoking theEUAL [procedures] now, rather thanwaiting
for amajor yellow fever vaccine shortage to occur.” Stewardship of
scarcevaccinesupplies is essential, but requires theWHO’sdirector-
general to declare a public health emergency of international con-
cern or determine it is “in the best interest of public health.”6 Given
the world’s vital health security interests, the WHO’s director-
general should use EUAL procedures to authorize a reduced vac-
cine dose to control the epidemic in Angola.
Time to Convene an Emergency Committee
It is only by convening an emergency committee that the WHO’s
director-general could declare a public health emergency of inter-
national concern. Whether this emergency committee recom-
mends declaring a public health emergency of international con-
cern, it would advise theWHO’s director-general on responding to
ongoing and future yellow fever outbreaks. There are strong rea-
sons to conveneanemergencycommitteenow.The looming threat
of a severe yellow fever vaccine shortage exists amid epidemics in
Africa, and potentially in Latin America and Asia. Even if the emer-
gency committee does not recommend a public health emergency
of international concern, it could recommend invoking EUAL pro-
cedures for use of a reduced vaccine dose.
Among multiple needed steps, the WHO’s director-general
(based on the emergency committee’s advice) should convene and
coordinate stakeholder meetings with yellow fever vaccine manu-
facturers to catalyze a surge in production; incentivize and coordi-
nate innovation in research and development for non–egg-based
yellow fever vaccines; coordinate mosquito vector control for yel-
low fever, benefitting also prevention measures for the ongoing
Zika virus epidemic. Recommendations are already in place to pre-
vent infections by vaccinating travelers to Angola. Convening a yel-
low fever emergency committee would not require a declaration of
a public health emergency of international concern, as demon-
strated by 10 Middle East respiratory syndrome committees con-
vened between 2013 and 2015, in which a global health emergency
was not declared.
Going Forward: A Standing Emergency Committee
TheWHOhas respondedmuchmorequickly to this yellowfeverepi-
demic than with either the Ebola virus or even the Zika virus. The
WHO’sdirector-general traveledtoAngola inearlyApril,workingwith
international partners to roll out a mass yellow fever vaccination
campaign—expressing the concern that “thewhole world could be
at risk” of a yellow fever epidemic. Global health advocates should
nothavetocall forconveninganemergencycommittee foreachnew
international health threat. Instead, the WHO should establish a
standingemergency committee8 tomeet regularly to advise thedi-
rector-general whether to declare an emergency, take necessary
steps to avert a crisis, or both. The complexities and apparent in-
creased frequency of emerging infectious disease threats, and the
catastrophic consequences of delays in the international response,
make it no longer tenable to place the sole responsibility and au-
thoritywith theWHO’sdirector-general toconvenecurrently adhoc
emergency committees. As the WHO begins the election cam-
paign for a new director-general, it is an opportune moment to
strengthen its capacity and leadership in global health security.
TheUN’shigh-levelpanelontheglobalhealthcrisescalledEbola
a “preventable tragedy.” If the ongoing panepidemics of Zika-
caused neurological syndromes or yellow fever eventually lead to
catastrophicconsequences, thenthepanel’sadmonitioncouldcome
true: “If theWHOdoesnot successfully reform, thenextmajor pan-
demic will cause thousands of otherwise preventable deaths. This
may be the last opportunity to ensure that theWHO is empowered
tobuild aneffective emergencypreparedness and response capac-
ity with the necessary political leadership. Another failure to per-
formmaynecessitate considerationof alternateUN institutional re-
sponsemechanisms.”9
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